COMP <GO>
KNSA vs ABVX // 10Y YIELD & FRED MACRO BETA
Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) VS. Abivax SA (NASDAQ) • 15-METRIC TALLY: KNSA 5
— ABVX 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: KNSA
LAST: $90.80 (-1.56%) • MKT CAP: $7.13B
macro-sensitivity
1.11
LAST: $84.91 (-1.94%) • MKT CAP: $7.41B
macro-sensitivity
1.05
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. ABVX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | ABVX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 9.90% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 21.0x | +74.00 | ABVX | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 2.21% | -0.43 | ABVX | /fcf-yield <GO> |
| Operating Margin | 11.40% | 13.90% | -2.50 | ABVX | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 10.90% | -2.20 | ABVX | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 8.80% | +51.30 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.45 | 3.74 | +20.71 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 38.7 | +18.50 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.11 | 1.05 | +0.06 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 30.5x | +78.60 | ABVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.13B | $7.41B | -$274.4M | ABVX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | ABVX REV | KNSA GROSS % | ABVX GROSS % | KNSA FCF | ABVX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | — | 88.5% | — | $136.4M | — |
| FY 2024 | $423.2M | — | 85.6% | — | $25.4M | — |
| FY 2023 | $270.3M | — | — | — | $1.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
ABVX // BETA 1.05